CymaBay Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
CymaBay Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| collaboration revenue | 57,000 | 31,016,000 | 5,207,000 | 4,793,000 | ||||||||||||||||||||||||||||||||||||||
| operating expenses: | ||||||||||||||||||||||||||||||||||||||||||
| research and development | 22,749,000 | 19,962,000 | 19,537,000 | 18,551,000 | 16,230,000 | 15,459,000 | 17,891,000 | 18,415,000 | 18,405,000 | 17,010,000 | 16,745,000 | 12,382,000 | -25,158,118 | 7,743,000 | 7,942,000 | 9,509,000 | -62,816,163 | 23,193,000 | 21,119,000 | 18,588,000 | 16,397,000 | 17,853,000 | 14,397,000 | 9,477,000 | 6,669,000 | 4,184,000 | 4,044,000 | 4,041,000 | 3,848,000 | 3,534,000 | 4,131,000 | 4,428,000 | 4,051,000 | 4,528,000 | 4,260,000 | 4,187,000 | 5,277,000 | 3,848,000 | 4,083,000 | 2,615,000 | 1,363,000 | 703,000 |
| general and administrative | 19,806,000 | 12,245,000 | 11,578,000 | 8,324,000 | 7,247,000 | 5,904,000 | 5,878,000 | 6,087,000 | 6,104,000 | 5,179,000 | 6,521,000 | 5,236,000 | -12,221,575 | 4,494,000 | 3,398,000 | 4,347,000 | -14,686,762 | 4,514,000 | 4,529,000 | 5,663,000 | 4,158,000 | 3,276,000 | 3,574,000 | 3,373,000 | 2,894,000 | 2,210,000 | 3,582,000 | 3,701,000 | 2,839,000 | 2,130,000 | 2,215,000 | 2,461,000 | 1,796,000 | 2,201,000 | 2,285,000 | 2,589,000 | 2,332,000 | 1,687,000 | 1,666,000 | 2,500,000 | 2,091,000 | 683,000 |
| total operating expenses | 42,555,000 | 32,207,000 | 31,115,000 | 26,875,000 | 23,477,000 | 21,363,000 | 23,769,000 | 24,502,000 | 24,509,000 | 22,189,000 | 23,266,000 | 17,618,000 | -36,676,398 | 11,650,000 | 11,152,000 | 13,927,000 | -77,497,850 | 27,707,000 | 25,648,000 | 24,251,000 | 20,555,000 | 21,129,000 | 17,971,000 | 12,850,000 | 9,563,000 | 6,394,000 | 7,626,000 | 7,742,000 | 6,687,000 | 5,664,000 | 6,346,000 | 6,889,000 | 5,847,000 | 6,729,000 | 6,545,000 | 6,776,000 | 7,609,000 | 5,535,000 | 5,749,000 | 5,115,000 | 3,454,000 | 1,386,000 |
| income from operations | -42,498,000 | -32,207,000 | -99,000 | -26,875,000 | -23,477,000 | -21,363,000 | -23,769,000 | -24,502,000 | -24,509,000 | -22,189,000 | -23,266,000 | -17,618,000 | 36,676,398 | -11,650,000 | -11,152,000 | -13,927,000 | 77,497,850 | -27,707,000 | -25,648,000 | -24,251,000 | -20,555,000 | -21,129,000 | -17,971,000 | -12,850,000 | -4,356,000 | -6,394,000 | -7,626,000 | -2,949,000 | -6,687,000 | -5,664,000 | -6,346,000 | -6,889,000 | -5,847,000 | -6,729,000 | -6,545,000 | -6,776,000 | -7,609,000 | -5,535,000 | -5,749,000 | -5,115,000 | -3,454,000 | -1,386,000 |
| yoy | 81.02% | 50.76% | -99.58% | 9.68% | -4.21% | -3.72% | 2.16% | 39.07% | -166.82% | 90.46% | 108.63% | 26.50% | -52.67% | -57.95% | -56.52% | -42.57% | -477.03% | 31.13% | 42.72% | 88.72% | 371.88% | 230.45% | 135.65% | 335.74% | -34.86% | 12.89% | 20.17% | -57.19% | 14.37% | -15.83% | -3.04% | 1.67% | -23.16% | 21.57% | 13.85% | 32.47% | 120.30% | 299.35% | ||||
| qoq | 31.95% | 32432.32% | -99.63% | 14.47% | 9.90% | -10.12% | -2.99% | -0.03% | 10.46% | -4.63% | 32.06% | -148.04% | -414.82% | 4.47% | -19.93% | -117.97% | -379.70% | 8.03% | 5.76% | 17.98% | -2.72% | 17.57% | 39.85% | 195.00% | -31.87% | -16.16% | 158.60% | -55.90% | 18.06% | -10.75% | -7.88% | 17.82% | -13.11% | 2.81% | -3.41% | -10.95% | 37.47% | -3.72% | 12.39% | 48.09% | 149.21% | |
| operating margin % | ||||||||||||||||||||||||||||||||||||||||||
| other income, net: | ||||||||||||||||||||||||||||||||||||||||||
| interest income | 5,680,000 | 3,170,000 | 2,627,000 | 2,013,000 | 919,000 | 677,000 | 321,000 | 98,000 | 27,000 | 29,000 | 44,000 | 67,000 | -1,492,384 | 229,000 | 426,000 | 839,000 | -4,205,658 | 1,425,000 | 1,610,000 | 1,176,000 | 1,106,000 | 1,113,000 | 1,061,000 | 708,000 | 324,000 | 216,000 | 44,000 | 37,000 | 30,000 | 45,000 | 48,000 | 53,000 | 61,000 | 46,000 | 26,000 | 27,000 | 26,000 | 19,000 | 17,000 | 12,000 | 9,000 | 0 |
| interest expense | -5,081,000 | -4,843,000 | -4,618,000 | -4,403,000 | -4,075,000 | -3,819,000 | -3,648,000 | -3,365,000 | -2,061,000 | -522,000 | -128,000 | -208,000 | -234,000 | -258,000 | -283,000 | -305,000 | -328,000 | -341,000 | -336,000 | -332,000 | -329,000 | -265,000 | -165,000 | -154,000 | -190,000 | -191,000 | -189,000 | -184,000 | -182,000 | -219,000 | ||||||||||||
| other income | -3,000 | -2,000 | 1,282,000 | 487,000 | 2,000 | 1,453,000 | -86,000 | -4,655,000 | -777,000 | -1,798,000 | -1,064,000 | -2,134,000 | 33,000 | 81,000 | -358,000 | 320,000 | 136,000 | 1,083,000 | 5,327,000 | 4,575,000 | -4,949,000 | -254,000 | 2,749,000 | -4,775,000 | -287,000 | 298,000 | ||||||||||||||||
| total other income | 596,000 | -1,675,000 | -709,000 | -1,903,000 | -2,433,500 | -3,142,000 | -3,325,000 | -3,267,000 | -2,034,000 | -493,000 | -1,492,384 | 229,000 | 426,000 | 839,000 | -4,205,658 | 1,425,000 | 1,610,000 | 1,176,000 | 1,106,000 | 2,566,000 | ||||||||||||||||||||||
| net income | -41,902,000 | -33,882,000 | -808,000 | -28,778,000 | -26,633,000 | -24,505,000 | -27,094,000 | -27,769,000 | -26,543,000 | -22,682,000 | -23,222,000 | -17,551,000 | 35,184,014 | -11,421,000 | -10,726,000 | -13,088,000 | 73,292,192 | -26,282,000 | -24,038,000 | -23,075,000 | -19,449,000 | -18,563,000 | -17,531,000 | -17,005,000 | -5,043,000 | -8,234,000 | -8,929,000 | -5,351,000 | -6,952,000 | -5,879,000 | -6,992,000 | -6,848,000 | -5,979,000 | -5,865,000 | -1,357,000 | -2,328,000 | -12,722,000 | -5,961,000 | -3,172,000 | -10,062,000 | -3,914,000 | -1,307,000 |
| yoy | 57.33% | 38.27% | -97.02% | 3.63% | 0.34% | 8.04% | 16.67% | 58.22% | -175.44% | 98.60% | 116.50% | 34.10% | -51.99% | -56.54% | -55.38% | -43.28% | -476.84% | 41.58% | 37.12% | 35.70% | 285.66% | 125.44% | 96.34% | 217.79% | -27.46% | 40.06% | 27.70% | -21.86% | 16.27% | 0.24% | 415.25% | 194.16% | -53.00% | -1.61% | -57.22% | -76.86% | 225.04% | 356.08% | ||||
| qoq | 23.67% | 4093.32% | -97.19% | 8.05% | 8.68% | -9.56% | -2.43% | 4.62% | 17.02% | -2.33% | 32.31% | -149.88% | -408.06% | 6.48% | -18.05% | -117.86% | -378.87% | 9.34% | 4.17% | 18.64% | 4.77% | 5.89% | 3.09% | 237.20% | -38.75% | -7.78% | 66.87% | -23.03% | 18.25% | -15.92% | 2.10% | 14.53% | 1.94% | 332.20% | -41.71% | -81.70% | 113.42% | 87.93% | -68.48% | 157.08% | 199.46% | |
| net income margin % | ||||||||||||||||||||||||||||||||||||||||||
| other comprehensive income: | -3,000 | -12,000 | 1,000 | -1,000 | ||||||||||||||||||||||||||||||||||||||
| unrealized gain on marketable securities, net of tax | 206,000 | 62,000 | -54,000 | 256,000 | -3,000 | -12,000 | 1,000 | -1,000 | 4,750 | 3,000 | -4,000 | |||||||||||||||||||||||||||||||
| total other comprehensive income | 206,000 | 62,000 | -54,000 | -2,250 | -2,000 | 7,000 | -2,072 | -104,000 | 316,000 | -210,000 | 58,750 | -51,000 | 183,000 | 103,000 | 3,250 | 36,000 | ||||||||||||||||||||||||||
| comprehensive loss | -41,696,000 | -33,820,000 | -862,000 | -28,522,000 | -26,385,000 | -24,638,000 | -27,316,000 | -27,975,000 | -26,555,000 | -22,684,000 | -23,215,000 | -17,565,000 | 35,181,942 | -11,525,000 | -10,410,000 | -13,298,000 | 73,057,330 | -26,333,000 | -23,855,000 | -22,972,000 | -19,476,000 | -18,527,000 | -17,466,000 | -17,093,000 | -5,074,000 | -8,246,000 | -8,928,000 | -5,352,000 | -6,951,000 | -5,876,000 | -6,996,000 | -6,828,000 | -5,992,000 | -5,860,000 | -1,363,000 | -2,321,000 | -12,721,000 | -5,976,000 | -3,174,000 | -10,061,000 | 5,377,000 | -4,343,000 |
| basic and diluted net income per common share | -370 | -320 | -10 | -290 | -310 | -280 | -310 | -320 | -350 | -330 | -340 | -250 | 509.26 | -170 | -1,020 | |||||||||||||||||||||||||||
| weighted-average common shares outstanding used to calculate basic and diluted net income per common share | 106,204,273,000 | 105,717,996,000 | 102,150,390,000 | 97,971,081,000 | 87,804,063,000 | 87,804,272,000 | 87,802,939,000 | 87,802,939,000 | 71,055,331,000 | 69,022,937,000 | 68,985,461,000 | 68,946,092,000 | 68,893,127 | 68,887,092,000 | 9,873,687,000 | |||||||||||||||||||||||||||
| other comprehensive loss: | -88,000 | |||||||||||||||||||||||||||||||||||||||||
| total other comprehensive loss | 256,000 | 248,000 | -133,000 | -206,000 | -14,000 | |||||||||||||||||||||||||||||||||||||
| unrealized loss on marketable securities | -140,250 | -133,000 | -206,000 | -14,000 | -88,000 | -4,250 | -15,000 | |||||||||||||||||||||||||||||||||||
| unrealized gain on marketable securities | -222,000 | -2,250 | -2,000 | 7,000 | -2,072 | -104,000 | 316,000 | -210,000 | -234,862 | -51,000 | 183,000 | 103,000 | -27,000 | 36,000 | 65,000 | 20,000 | 1,500 | 5,000 | -6,000 | 7,000 | -2,000 | 1,000 | ||||||||||||||||||||
| total other comprehensive gain | -222,000 | |||||||||||||||||||||||||||||||||||||||||
| restructuring charges | -176,000 | -587,000 | -188,000 | 71,000 | ||||||||||||||||||||||||||||||||||||||
| other income: | ||||||||||||||||||||||||||||||||||||||||||
| basic net income per common share | -160 | -190 | 1,098.47 | -380 | -350 | -370 | -320 | -310 | -300 | -320 | -80 | -210 | -310 | -200 | -300 | -250 | -300 | -290 | -270 | -270 | -90 | -150 | -930 | -440 | -320 | 536,850 | 422,950 | |||||||||||||||
| diluted net income per common share | -160 | -190 | 1,098.47 | -380 | -350 | -370 | -330 | -340 | -300 | -320 | -80 | -210 | -310 | -200 | -300 | -250 | -300 | -290 | -250 | -270 | -90 | -440 | -930 | -440 | -560 | 5,400 | -1,790 | |||||||||||||||
| weighted-average common shares outstanding used to calculate basic net income per common share | 68,885,108,000 | 68,882,459,000 | 67,033,046 | 68,701,043,000 | 68,697,735,000 | 61,890,632,000 | 57,808,254,000 | 59,121,600,000 | 58,833,647,000 | 53,752,753,000 | 34,903,960,000 | 40,035,690,000 | 28,752,451,000 | 26,609,931,000 | 23,447,003,000 | 23,447,003,000 | 23,447,003,000 | 23,447,003,000 | 18,900,473,000 | 21,674,742,000 | 15,258,363,000 | 15,099,567,000 | 12,048,985,000 | 13,468,081,000 | 10,064,819,000 | 101,358,000 | ||||||||||||||||
| weighted-average common shares outstanding used to calculate diluted net income per common share | 68,885,108,000 | 68,882,459,000 | 67,033,046 | 68,701,043,000 | 68,697,735,000 | 61,890,632,000 | 57,838,299,000 | 59,387,780,000 | 58,905,898,000 | 53,752,753,000 | 34,903,960,000 | 40,035,690,000 | 28,752,451,000 | 26,609,931,000 | 23,447,003,000 | 23,447,003,000 | 23,447,003,000 | 23,447,003,000 | 18,917,213,000 | 21,674,742,000 | 15,258,363,000 | 15,743,167,000 | 12,048,985,000 | 13,468,081,000 | 10,487,393,000 | 2,845,609,000 | 731,970,000 | |||||||||||||||
| loss on extinguishment of debt | -407,000 | |||||||||||||||||||||||||||||||||||||||||
| other comprehensive income | 65,000 | 1,000 | 3,000 | -4,000 | 20,000 | 1,500 | 5,000 | -6,000 | 7,000 | -2,000 | 1,000 | |||||||||||||||||||||||||||||||
| net income attributable to common stockholders | -12,722,000 | -5,961,000 | -3,172,000 | -10,062,000 | ||||||||||||||||||||||||||||||||||||||
| other comprehensive loss | 1,000 | -15,000 | ||||||||||||||||||||||||||||||||||||||||
| accretion to redemption value of redeemable convertible preferred stock | -2,322,250 | -3,036,000 | ||||||||||||||||||||||||||||||||||||||||
| other comprehensive loss/income: | ||||||||||||||||||||||||||||||||||||||||||
| contract revenue | ||||||||||||||||||||||||||||||||||||||||||
| net income attributable to stockholders | -3,862,000 | -4,343,000 | ||||||||||||||||||||||||||||||||||||||||
| unrealized losses on marketable securities |
We provide you with 20 years income statements for CymaBay Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CymaBay Therapeutics stock. Explore the full financial landscape of CymaBay Therapeutics stock with our expertly curated income statements.
The information provided in this report about CymaBay Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.